Identifai-Genetics is pioneering a new approach to prenatal genetic testing through its advanced bioinformatics technology. The company focuses on non-invasive prenatal screening by analyzing cell-free DNA (cfDNA) circulating in maternal blood. This innovative method allows for the early detection of a wide range of genetic syndromes, significantly surpassing the capabilities of existing screening methods, which currently identify less than 10% of known genetic disorders. By utilizing a simple blood draw from the mother during the first trimester, Identifai's proprietary algorithms can isolate and reconstruct the fetus's DNA at high resolution, enabling the identification of actionable genetic variants.

The technology developed by Identifai-Genetics not only enhances the accuracy of prenatal testing but also provides comprehensive coverage of genetic conditions, from point mutations to chromosomal anomalies. This approach addresses the limitations of traditional invasive tests, such as amniotic fluid sampling, which carry risks and are often performed later in pregnancy. Through strategic partnerships and large-scale clinical studies, Identifai aims to establish a new standard in prenatal testing, offering expectant parents peace of mind with early and reliable insights into their fetus's health.

Israel

By taking a simple blood test from the mother-to-be, we can read the fetal DNA!
No more risky, complicated and late invasive tests like amniocentesis - we are revolutionizing the way prenatal testing is done.

Identifai-Genetics

Company Details